Clinical Trials Arena on MSN6d
Immunovant will not seek approval for MG therapy, despite hitting endpointsImmunovant will use results from its Phase III myasthenia gravis study to support pipeline candidate IMVT-1402 over the trial ...
The drug is already FDA-approved for other Soliris indications, including paroxysmal nocturnal haemoglobinuria (PNH), haemolytic uraemic syndrome (HUS), and generalised myasthenia gravis (gMG).
Dr Nicholas Silvestri looks ahead to new data on existing agents and emerging therapies for myasthenia gravis.
Dr Nicholas Silvestri shares AAN 2025 highlights, including anticipated presentations, quick takeaways, and insights on the ...
Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half ...
Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to ...
Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG), one of two drugs that the company hopes will shake up the ...
Research also showed that the test has a very low false positive rate. VolitionRx Limited announced that its Nu.Q cancer immunoassay test was able to detect at least 21 different cancers in a recent ...
Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback